Fennec Pharmaceuticals Inc (FENC) reports a 75% increase in Q4 net product sales, debt-free status, and strategic market expansions amid rising expenses.

Delivered Record Annual Revenue with Full-Year Net PEDMARK® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 ...

Fennec Pharmaceuticals reported record commercial growth for PEDMARK during its fourth quarter and full year 2025 earnings ...